{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:29:45Z","timestamp":1747193385061,"version":"3.40.5"},"reference-count":24,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intervirology"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; Foot-and-mouth disease virus (FMDV) causes a highly contagious disease in cloven-hoofed animals and is the most damaging disease of livestock worldwide, leading to great economic losses. The aim of this research was the inactivation of FMDV type O\/IRN\/1\/2007 to produce a gamma ray-irradiated (GRI) vaccine in order to immunize mice and guinea pigs. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; In this research, the Iranian isolated FMDV type O\/IRN\/1\/2007 was irradiated by gamma ray to prepare an inactivated whole virus antigen and formulated as a GRI vaccine with unaltered antigenic characteristics. Immune responses against this vaccine were evaluated on mice and guinea pigs. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; The comparison of the immune responses between the GRI vaccine and conventional vaccine did not show any significant difference in neutralizing antibody titer, memory spleen T lymphocytes or IFN-&amp;#947;, IL-4, IL-2 and IL-10 concentrations (p &gt; 0.05). In contrast, there were significant differences in all of the evaluated immune factors between the two vaccinated groups of mice and negative control mice (p &lt; 0.05). The protective dose 50 for the conventional and GRI vaccines obtained were 6.28 and 7.07, respectively, which indicated the high potency of both vaccines. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; GRI vaccine is suitable for both routine vaccination and control of FMDV in emergency outbreaks.<\/jats:p>","DOI":"10.1159\/000433538","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T21:01:35Z","timestamp":1437512495000},"page":"190-196","source":"Crossref","is-referenced-by-count":10,"title":["Development of Protective Immunity against Inactivated Iranian Isolate of Foot-and-Mouth Disease Virus Type O\/IRN\/2007 Using Gamma Ray-Irradiated Vaccine on BALB\/c Mice and Guinea Pigs"],"prefix":"10.1159","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1924-4959","authenticated-orcid":false,"given":"Farahnaz","family":"Motamedi-Sedeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoorieh","family":"Soleimanjahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Reza","family":"Jalilian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homayoon","family":"Mahravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalodin","family":"Shafaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masood","family":"Sotoodeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamdolah","family":"Taherkarami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faramarz","family":"Jairani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11250-012-0077-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00169-3"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)00250-X"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.20.11290-11295.2003"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.048"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)00250-X"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-012-3258-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.1973.tb02055.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000440"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.093"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.034"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-64-2-341"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90092-X"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90083-X"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2009.81"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5772\/34901"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/308658a0"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/1359-0197(90)90275-M"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12088-008-0023-4"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005336"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.12.049"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.034"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90171-S"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400028643"}],"container-title":["Intervirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/433538","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/433538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/433538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:15:17Z","timestamp":1745432117000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000433538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,8,1]]},"published-print":{"date-parts":[[2015,8,25]]}},"URL":"https:\/\/doi.org\/10.1159\/000433538","archive":["Portico"],"relation":{},"ISSN":["0300-5526","1423-0100"],"issn-type":[{"type":"print","value":"0300-5526"},{"type":"electronic","value":"1423-0100"}],"subject":[],"published":{"date-parts":[[2015]]}}}